TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8383403

Group type: EXPERIMENTAL
Intervention: 50% combination of alcuronium (0.125 mg.kg‐1) and tubocurarine (0.255 mg.kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcuronium alone (0.25 mg.kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tubocurarine alone (0.51 mg.kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 33% combination of alcuronium and tubocurarine
Number of subjects: 0
Study: 3549739

Group type: EXPERIMENTAL
Intervention: Intra-aortic administration of protamine sulphate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intra-right atrial administration of protamine sulphate
Number of subjects: 20
Study: 31347012

Group type: EXPERIMENTAL
Intervention: dDAVP (lyophilizate 120 μg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: New age- and weight-based dosing regimen
Number of subjects: 100
Study: 29952004

Group type: EXPERIMENTAL
Intervention: UTTR1147A (IL-22Fc) administered intravenously (i.v.) at doses of 1-120 μg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UTTR1147A (IL-22Fc) administered subcutaneously (s.c.) at doses of 3-120 μg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UTTR1147A (IL-22Fc)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28086766

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention, consisting of 6 sessions (1 individual and 5 group) offered by a psychologist, in addition to treatment as usual.
Number of subjects: 600

Group type: COMPARATOR
Intervention: Treatment as usual (control group).
Number of subjects: 600
Study: 26101366

Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine (3-dose regimen at day 1, month 2, month 6)
Number of subjects: 3066
Study: 23703247

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 70

Group type: COMPARATOR
Intervention: FOLFOXIRI/XELOXIRI
Number of subjects: 70
Study: 21878824

Group type: EXPERIMENTAL
Intervention: Resistance followed by aerobic exercise (R‐A)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Aerobic followed by resistance exercise (A‐R)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Both R‐A and A‐R
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: A‐R
Number of subjects: 7
Study: 19490293

Group type: EXPERIMENTAL
Intervention: Lindsay Leg Club model of care
Number of subjects: 67

Group type: COMPARATOR
Intervention: Traditional community nursing model
Number of subjects: 67
Study: 17065355

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 2748

Group type: COMPARATOR
Intervention: Blood glucose >150 mg/dl
Number of subjects: 2748

Group type: COMPARATOR
Intervention: Blood glucose <110 mg/dl
Number of subjects: 2748

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 2748
Study: 15170708

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual abciximab administration
Number of subjects: 45
Study: 11641678

Group type: EXPERIMENTAL
Intervention: Misoprostol (25 microg vaginally on days 1 and 4)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (vaginally on days 1 and 4)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 9841947

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with ePTFE membranes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional flap surgery (previous treatment)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matched control patients who underwent conventional treatment alone
Number of subjects: 20
Study: 8135881

Group type: EXPERIMENTAL
Intervention: Intramuscular glucosamine sulfate 400 mg twice a week for 6 weeks
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 2913766

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 12
Study: 31138140

Group type: COMPARATOR
Intervention: Support staff
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Inadequate numbers of disposable respirators
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: TB stigma scale
Number of subjects: 882
Study: 28680341

Group type: EXPERIMENTAL
Intervention: One night sleep deprivation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Normal sleep
Number of subjects: 64
Study: 26307858

Group type: EXPERIMENTAL
Intervention: Drug treatment for chronic neuropathic pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug treatment
Number of subjects: 0
Study: 23543140

Group type: EXPERIMENTAL
Intervention: Silodosin (8 mg/daily for a maximum of 4 weeks)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (2 L of water daily)
Number of subjects: 112
Study: 22368896

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 107

Group type: COMPARATOR
Intervention: Ticarcillin/clavulanate
Number of subjects: 107
Study: 19436289

Group type: EXPERIMENTAL
Intervention: Self-expanding metal stents (SEMSs)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Non-stent treatments
Number of subjects: 215
Study: 16454836

Group type: EXPERIMENTAL
Intervention: Etoricoxib (60 to 120 mg tablet once a day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (tablet once a day)
Number of subjects: 76
Study: 15039128

Group type: EXPERIMENTAL
Intervention: Aggressive pharmacological treatment (using statins, beta-blockers, ACE-inhibitors, and aspirin)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Population-wide reductions in serum total cholesterol and systolic blood pressure
Number of subjects: 100
Study: 12604023

Group type: EXPERIMENTAL
Intervention: 20 mg of zafirlukast twice a day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 400 mg of budesonide twice a day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 20 mg of zafirlukast twice a day and 400 mg of budesonide twice a day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (12 healthy subjects)
Number of subjects: 36
Study: 9306141

Group type: EXPERIMENTAL
Intervention: AWOS QCA system
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cardio QCA system
Number of subjects: 57

Group type: COMPARATOR
Intervention: CMS QCA system
Number of subjects: 57

Group type: COMPARATOR
Intervention: Brown Dodge method
Number of subjects: 57
Study: 8232703

Group type: EXPERIMENTAL
Intervention: Acupuncture applied 3 times/week for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional supportive treatment
Number of subjects: 30
Study: 2446759

Group type: EXPERIMENTAL
Intervention: Isoprinosine (50 mg/kg) as pulse immunotherapy, schedule A: 5 days every 15 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoprinosine (50 mg/kg) as pulse immunotherapy, schedule B: 5 days every 15 days for 2 months, then 5 days every 2 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 30213617

Group type: EXPERIMENTAL
Intervention: Intervention group (n=5) received weekly boxes of fruits and vegetables and dietary counseling to increase consumption to 8 to 10 daily servings for 12 weeks.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (n=5) directed to the USDA's 'ChooseMyPlate' diet for pregnancy and breastfeeding.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both groups measured cytokine levels in breast milk at weeks 1 and 13.
Number of subjects: 10
Study: 28114849

Group type: EXPERIMENTAL
Intervention: Executive function under stress
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control task (non-stressful context)
Number of subjects: 110
Study: 26849552

Group type: EXPERIMENTAL
Intervention: International Physical Activity Questionnaire (IPAQ) in 2002
Number of subjects: 2751

Group type: EXPERIMENTAL
Intervention: Global Physical Activity Questionnaire (GPAQ) in 2011
Number of subjects: 2751
Study: 23300039

Group type: COMPARATOR
Intervention: Conventional CTA (Group A)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: CTA with novel OSDR algorithm (Group B)
Number of subjects: 62
Study: 20834044

Group type: EXPERIMENTAL
Intervention: Levodopa (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18342559

Group type: EXPERIMENTAL
Intervention: 50mg sildenafil
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16824221

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 42
Study: 14600926

Group type: EXPERIMENTAL
Intervention: CK‐MB increase > 50 IU/ml (group 1, n = 9)
Number of subjects: 36

Group type: COMPARATOR
Intervention: CK‐MB levels </= 50 IU/ml (group 2, n = 27)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group 1 (CK‐MB > 50 IU/ml)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group 2 (CK‐MB </= 50 IU/ml)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Increased CK‐MB level
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: New defect of perfusion found at follow-up MPI
Number of subjects: 36
Study: 10831545

Group type: EXPERIMENTAL
Intervention: GnRH agonist (triptorelin) with HMG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GnRH agonist (buserelin) with HMG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GnRH agonists (triptorelin or buserelin) with HMG
Number of subjects: 0

Group type: COMPARATOR
Intervention: HMG alone
Number of subjects: 0
Study: 9104522

Group type: EXPERIMENTAL
Intervention: 3 mg granisetron (approximately 60 micrograms.kg‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1.25 mg droperidol (approximately 25 micrograms.kg‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80
Study: 8182634

Group type: EXPERIMENTAL
Intervention: Home physiotherapy treatment program
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (previously withheld treatment)
Number of subjects: 46
Study: 3372681

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg orally) + Alcohol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Naltrexone (50 mg orally) + Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg orally)
Number of subjects: 14
Study: 31063475

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) and Sofosbuvir (SOF) therapy
Number of subjects: 132
Study: 28163113

Group type: EXPERIMENTAL
Intervention: Olive or sunflower oil yarrow extracts applied topically for seven days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25160493

Group type: EXPERIMENTAL
Intervention: Calcium aluminosilicate clay (CASAD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 23238657

Group type: EXPERIMENTAL
Intervention: AGE‐modified β‐lactoglobulins (AGE‐BLG)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Heat‐treated, nonglycated β‐lactoglobulins (C‐BLG)
Number of subjects: 19
Study: 21572353

Group type: EXPERIMENTAL
Intervention: Muscle damage group (plyometric exercise)
Number of subjects: 17
Study: 18420373

Group type: EXPERIMENTAL
Intervention: Simulators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Criterion scores
Number of subjects: 0
Study: 16405734

Group type: EXPERIMENTAL
Intervention: Drip-push (4 modules weekly over 10 weeks by email)
Number of subjects: 1267

Group type: EXPERIMENTAL
Intervention: Drip-pull (modules accessible on website with 4 reminders weekly for 10 weeks)
Number of subjects: 1267

Group type: EXPERIMENTAL
Intervention: Bolus-push (40 modules delivered within 4 days by email)
Number of subjects: 1267

Group type: EXPERIMENTAL
Intervention: Bolus-pull (40 modules available on the Internet with one email informing participants of availability)
Number of subjects: 1267
Study: 14609565

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: General Anesthesia plus Thoracic Epidural Block (TEB)
Number of subjects: 26
Study: 12922085

Group type: EXPERIMENTAL
Intervention: Full adult dose of tick-borne encephalitis vaccine
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Half adult dose of tick-borne encephalitis vaccine
Number of subjects: 595
Study: 10381173

Group type: EXPERIMENTAL
Intervention: rgp160
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 8678275

Group type: EXPERIMENTAL
Intervention: Sevoflurane (S)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Halothane (H)
Number of subjects: 40
Study: 1832424

Group type: EXPERIMENTAL
Intervention: 75 g glucose dose
Number of subjects: 7

Group type: COMPARATOR
Intervention: sham control (distilled water)
Number of subjects: 7
Study: 6388716

Group type: EXPERIMENTAL
Intervention: Cephazolin (given either pre‐operatively or into the wound)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 375
Study: 3527371

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31081224

Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 275

Group type: COMPARATOR
Intervention: Peer modelling (high vs. low)
Number of subjects: 275
Study: 29053645

Group type: EXPERIMENTAL
Intervention: High-speed drilling with irrigation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low-speed drilling without irrigation
Number of subjects: 25
Study: 24267102

Group type: EXPERIMENTAL
Intervention: Enhanced Care (EC)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Supported Care (SC)
Number of subjects: 105
Study: 23277234

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo responders
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo nonresponders
Number of subjects: 71
Study: 20852882

Group type: EXPERIMENTAL
Intervention: Unilateral leg immobilization for 12 days
Number of subjects: 15
Study: 18438908

Group type: EXPERIMENTAL
Intervention: Cumulative prednisone dosage in multiple flares subgroup: 7.9 gm
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Cumulative prednisone dosage in single flare subgroup: 6.0 gm
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Cumulative prednisone dosage in remission subgroup: 3.9 gm
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: New diagnosis of Wegener's granulomatosis at baseline
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Patients in remission subgroup (40 patients)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Overall weight gain >10 kg
Number of subjects: 168
Study: 16854754

Group type: EXPERIMENTAL
Intervention: Combined low-dose azathioprine (0.6-0.75 mg/kg) and oral PUVA therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral PUVA therapy alone
Number of subjects: 60
Study: 15331546

Group type: EXPERIMENTAL
Intervention: Gastric inhibitory polypeptide (GIP) infusion (2 pmol. kg(‐1). min(‐1), 60‐115 min)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: GIP infusion
Number of subjects: 13

Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 13
Study: 11557836

Group type: EXPERIMENTAL
Intervention: Balanced-deficit diets
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Low-calorie diets
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo effects
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Lifestyle treatments
Number of subjects: 108
Study: 9263089

Group type: EXPERIMENTAL
Intervention: Ulinastatin (600,000 U in total)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 18
Study: 8427943

Group type: EXPERIMENTAL
Intervention: Temocapril HCl (0.5 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Temocapril HCl (1.0 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Temocapril HCl (2.0 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Temocapril HCl
Number of subjects: 6
Study: 3326213

Group type: EXPERIMENTAL
Intervention: Enteric coated microspheres of pancreatin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard enteric coated preparation
Number of subjects: 23
Study: 29253350

Group type: EXPERIMENTAL
Intervention: Mosaicplasty
Number of subjects: 40

Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study: 26692449

Group type: COMPARATOR
Intervention: Continuous CS-UCS pairings (C-C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial followed by continuous CS-UCS pairings (P-C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous followed by partial CS-UCS pairings (C-P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial CS-UCS pairings during acquisition (P-P)
Number of subjects: 0
Study: 25910983

Group type: EXPERIMENTAL
Intervention: Intervention group (goal for steps taken per day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no specific goal for steps taken)
Number of subjects: 55
Study: 23002086

Group type: EXPERIMENTAL
Intervention: Interval-walking group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Continuous-walking group
Number of subjects: 32
Study: 20639713

Group type: EXPERIMENTAL
Intervention: Muffins containing 4 mg Fe as ferrous fumarate with orange juice (25 mg ascorbic acid)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Muffins containing 4 mg Fe as ferrous fumarate with apple juice (no ascorbic acid)
Number of subjects: 21
Study: 18348735

Group type: EXPERIMENTAL
Intervention: Narconon drug education curriculum
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (received drug education after the six-month follow-up)
Number of subjects: 1000
Study: 17288232

Group type: EXPERIMENTAL
Intervention: Antinicotine vaccines (TA-NIC, NicVAX, CYT002-NicQb)
Number of subjects: 0
Study: 12707149

Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (n = 16) at doses of up to 70 mL x kg(‐1) x d(‐1)
Number of subjects: 31

Group type: COMPARATOR
Intervention: HES 200/0.5 (n = 15) at doses of up to 33 mL x kg(‐1) x d(‐1) followed by human albumin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (n = 16)
Number of subjects: 31
Study: 11032216

Group type: EXPERIMENTAL
Intervention: Periodized multiple-set resistance training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single-set circuit resistance training
Number of subjects: 24

Group type: COMPARATOR
Intervention: No resistance exercise control group
Number of subjects: 24
Study: 9321529

Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (induction treatment)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Chemotherapy (daunorubicin plus cytarabine) (induction treatment)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (maintenance treatment)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Chemotherapy (maintenance treatment)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (induction and maintenance treatment)
Number of subjects: 346
Study: 8416719

Group type: EXPERIMENTAL
Intervention: Outpatient chemotherapy
Number of subjects: 259
Study: 3546124

Group type: EXPERIMENTAL
Intervention: Oral diclofenac (prostaglandin inhibitor) for 1 week after splintage removal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30230538

Group type: EXPERIMENTAL
Intervention: Independent group contingency
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Randomized dependent group contingency
Number of subjects: 9

Group type: COMPARATOR
Intervention: Independent group contingency and Randomized dependent group contingency
Number of subjects: 9
Study: 27701369

Group type: EXPERIMENTAL
Intervention: Transaortic approach (TAo)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Transaxillary approach (TAx)
Number of subjects: 242
Study: 26520217

Group type: EXPERIMENTAL
Intervention: Internet-delivered exposure (EX)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Waiting-list (Control)
Number of subjects: 47
Study: 23797378

Group type: EXPERIMENTAL
Intervention: Peripheral nerve block (PNB) using computer-controlled local anesthetic delivery (CCLAD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Topical anesthesia
Number of subjects: 50
Study: 21785360

Group type: EXPERIMENTAL
Intervention: Traditional consent (n = 110)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Binary consent (n = 103)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Tiered consent (n = 110)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 323
Study: 19359651

Group type: EXPERIMENTAL
Intervention: Recent respiratory tract infections
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Community-acquired respiratory tract infections
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Respiratory tract infections in the 3 months before an atherothrombotic ischemic event
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: History of respiratory infection in the prior year
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: White blood cell count
Number of subjects: 105
Study: 16963784

Group type: EXPERIMENTAL
Intervention: JUMP-in intervention
Number of subjects: 510

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 510
Study: 14754980

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (first-generation antihistamine)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cetirizine (second-generation antihistamine)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11111965

Group type: EXPERIMENTAL
Intervention: Converted group (early conversion from MMF to azathioprine at 4 months)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (late conversion from MMF to azathioprine after 12 months)
Number of subjects: 28
Study: 9379690

Group type: EXPERIMENTAL
Intervention: Octreotide (4 months therapy)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (surgical resection only)
Number of subjects: 32